HSP90AA1 and osteosarcoma: Silencing the HSP90AA1 gene reduces LC3II expression but increases Beclin-1 expression, thus enhancing the sensitivity of osteosarcoma cells to CDDP, DOX and methotrexate-based chemotherapy [226].